ALK and non-small cell lung carcinoma: EGFR mutations are frequent in the Colombian population (24.7%), which may be because of a large indigenous ancestry (approximately 29%).25,26ALK fusions, another predictive biomarker, occur in approximately 3% of nonsquamous NSCLC and must be identified because ALK inhibitors are highly effective.27 Immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), and RNA sequencing detect ALK positivity.